B+
Bull case
0%
Probability
Target price
$14.50
+45.9% vs current
VREX
Varex ImagingDNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
1%
Probability
Target price
$11.00
+10.7% vs current
B-
Bear case
0%
Probability
Target price
$8.50
-14.5% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+62.2
Score
AI commentary
This is a T+1 post-earnings monitoring setup, not a clean bullish reset. Primary-source evidence is solid, but the new information mostly confirms a mixed print: in-range revenue, softer margins, weak cash conversion, and modest second-half growth guidance. Immediate market reaction was negative, with VREX trading at $9.73 on May 8, 2026 versus the May 7, 2026 anchor close of $11.83, and trustworthy analyst revision detail was still unavailable at this stage.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-08eventFiscal Q2 results were in range, but the market is reacting to softer profitability and only modest second-half growth guidanceHigh impact
Varex reported fiscal Q2 revenue of $216.0 million, non-GAAP EPS of $0.21, and cash outflow from operations of $2 million. Management said demand remained solid across CT, cargo systems, and photon counting detectors, but non-GAAP gross margin fell to 34% from 36% a year earlier and full-year guidance of $860 million-$880 million revenue with $0.80-$1.00 non-GAAP EPS still leaves limited room for execution misses. The May 8, 2026 market reaction was sharply negative, with shares trading at $9.73 versus the May 7, 2026 anchor close of $11.83. [#8-K-2026-05-07]
2026-08-01catalystQ3 guidance becomes the next near-term test, with no IEEPA tariff refund assumedHigh impact
For fiscal Q3 2026, Varex guided to revenue of $210 million-$225 million and non-GAAP EPS of $0.15-$0.30, while explicitly stating that no IEEPA tariff refund is assumed in guidance. That keeps the near-term setup tied to whether demand in Medical and Industrial can offset material-cost pressure and tariff uncertainty. [#8-K-2026-05-07]
2026-09-30catalystBacklog and second-half demand can help the stock recover only if inventory converts to cash and margins stabilizeHigh impact
The 10-Q showed estimated backlog of about $266 million at April 3, 2026, while inventories rose to $346.7 million from $299.4 million at fiscal year-end and operating cash flow for the first six months was negative $17.6 million. Management said second-half fiscal 2026 revenue should be up about 3% year over year, but the longer thesis still depends on turning anticipated demand into shipments, cash generation, and better gross-margin performance. [#10-Q-2026-05-07] [#8-K-2026-05-07]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology